AEZS - Aeterna Zentaris Inc.
3.48 -0.03 (-0.85%)
After hours: 4:07PM EST
| Previous Close | 3.6600 |
| Open | 3.7000 |
| Bid | 3.48 x 800 |
| Ask | 3.58 x 1000 |
| Day's Range | 3.4500 - 3.7250 |
| 52 Week Range | 1.1200 - 3.9200 |
| Volume | 458,181 |
| Avg. Volume | 619,961 |
| Market Cap | 57.601M |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | 6.57 |
| EPS (TTM) | 0.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Zacks•3 days ago
Aeterna Zentaris (AEZS) Stock Moves -0.54%: What You Should Know
Aeterna Zentaris (AEZS) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day.
- Zacks•6 days ago
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
Is (AEZS) Outperforming Other Medical Stocks This Year?
- Zacks•10 days ago
Can The Uptrend Continue for Aeterna Zentaris (AEZS)?
Investors certainly have to be happy with Aeterna Zentaris Inc. (AEZS) and its short term performance.
- ACCESSWIRE•21 days ago
4 Healthcare Stocks Taking a New Approach to Growth Trends
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
- GlobeNewswire•21 days ago
Aeterna Zentaris (AEZS) Receives Positive CHMP Opinion of Macimorelin for Diagnosis of Adult Growth Hormone Deficiency
Aeterna Zentaris Inc. (AEZS) (AEZS), announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency (AGHD). The recommendation will now be reviewed by the European Commission. “We are pleased with the CHMP’s positive opinion of macimorelin for AGHD,” said Michael V. Ward, Chief Executive Officer of Aeterna Zentaris.
- ACCESSWIRE•24 days ago
4 Healthcare Stocks Turning Toward Tech For New Growth
CORAL GABLES, FL / ACCESSWIRE / November 16,2018 / There's no denying the progress that the healthcare industry has made. According to analyst firm Market Research Engine, the E-Health Market is expected to exceed more than US$136 Billion by 2024 at a CAGR of 21% in the given forecast period. Bank of America surveyed** 225 fund managers with $641 billion in assets under management, who said the most "crowded trade" is in tech stocks.
- GlobeNewswire•24 days ago
Consolidated Research: 2018 Summary Expectations for Western Gas Partners, LP, HCA Healthcare, DHI Group, AEterna Zentaris, Tsakos Energy Navigation, and Acme United — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Associated Press•last month
Aeterna Zentaris: 3Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 15 cents per share. The drug developer posted revenue of $663,000 in the period. In the final minutes of trading on Tuesday, the company's ...
- GlobeNewswire•last month
Aeterna Zentaris Reports Third Quarter 2018 Financial and Operating Results
CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a biopharmaceutical company engaged in developing and commercializing pharmaceutical.
- GlobeNewswire•last month
Aeterna Zentaris Settles Dispute with Cogas Consulting, LLC
CHARLESTON, S.C., Nov. 06, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) and Cogas Consulting, LLC have amicably resolved their dispute with Aeterna Zentaris Inc..
- ACCESSWIRE•last month
Aeterna Zentaris Soars on Macrilen(TM) Out Licensing Deal, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Aeterna Zentaris Inc. (AEZS), a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. In intra-day trading on October 31, 2018, Aeterna Zentaris is at $2.11 per share (+62.31%) in reaction to Strongbridge Biopharma's out-licensing deal with Novo Nordisk for U.S. and Canadian rights to the AEZS drug MACRILEN (macimorelin). Details of the Macrilen™ and the Novo Nordisk deal and analysts review here READ MORE.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Aeterna Zentaris and AbbVie
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Aeterna Zentaris saw its shares climbing as Wall Street learned about Novo Nordisk and Strongbridge Biopharma’s deal where Aeterna Zentaris stands to capitalize. ...
- ACCESSWIRE•last month
3 Healthcare Stocks Leading New Industry Trends
CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / Institutional investors' focus onhealthcare services has grown over the last several quarters. "Institutional investors have been learning from their experience and will likely be using those lessons as they inject hundreds of billions in capital into healthcare in the next five years. As these trends continue to foster investment, companies like Premier Health Group, Inc. (PHGRF) (PHGI.CN), Aeterna Zentaris Inc. (AEZS)(TSX:AEZS.TO) and Veracyte, Inc. (VCYT) could be positioned to capitalize on this growth.
- GlobeNewswire•2 months ago
Aeterna Zentaris Appoints Leslie Auld as Chief Financial Officer
Aeterna Zentaris Inc. (AEZS) (AEZS.TO), a biopharmaceutical company engaged in developing and commercializing pharmaceutical products, today announced the appointment of Leslie Auld as Senior Vice President, Chief Financial Officer. Ms. Auld has over twenty-five years of accounting, finance and pharmaceutical industry experience, with increasingly senior roles at PricewaterhouseCoopers, Helix BioPharma Corp., Luminex Diagnostics (formerly TM BioScience Corp.), Attwell Capital Inc. (formerly Fralex Therapeutics) and GeneNews Limited.
- Simply Wall St.•4 months ago
What is Behind Aeterna Zentaris Inc’s (TSE:AEZS) Superior ROE?
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. WithRead More...
- ACCESSWIRE•4 months ago
Aeterna Zentaris Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Aeterna Zentaris Inc. (NASDAQ: AEZS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern ...
- Associated Press•4 months ago
Aeterna Zentaris: 2Q Earnings Snapshot
The Summerville, South Carolina-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $168,000 in the period. In the final minutes of trading on Thursday, the company's ...
- Zacks•6 months ago
Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
- Zacks•7 months ago
VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher
VIVUS (VVUS) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
- Zacks•7 months ago
MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session
MiMedx Group (MDXG) shares rose more than 11% in the last trading session, amid huge volumes.
